[1]王雪云,孙 敏,赵巧云,等.聚乙二醇干扰素联合富马酸替诺福韦治疗慢性乙型肝炎的疗效观察[J].医学信息,2020,33(04):144-146.[doi:10.3969/j.issn.1006-1959.2020.04.046]
　WANG Xue-yun,SUN Min,ZHAO Qiao-yun,et al.Observation on the Efficacy of Pegylated Interferon Combined with Tenofovir Fumarate in the Treatment of Chronic Hepatitis B[J].Medical Information,2020,33(04):144-146.[doi:10.3969/j.issn.1006-1959.2020.04.046]
点击复制

聚乙二醇干扰素联合富马酸替诺福韦治疗慢性乙型肝炎的疗效观察()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年04期
页码:
144-146
栏目:
药物与临床
出版日期:
2020-02-15

文章信息/Info

Title:
Observation on the Efficacy of Pegylated Interferon Combined with Tenofovir Fumarate in the Treatment of Chronic Hepatitis B
文章编号:
1006-1959（2020）04-0144-03
作者:
王雪云; 孙 敏; 赵巧云; 等
（1.青岛大学研究生院，山东 青岛 266071；2.济宁市传染病医院，山东 济宁 272031；3.青岛大学附属医院感染性疾病科，山东 青岛 266071）
Author(s):
WANG Xue-yun; SUN Min; ZHAO Qiao-yun; et al
(1.Graduate School,Qingdao University,Qingdao 266071,Shandong,China;2.Jining Infectious Disease Hospital,Jining 272031,Shandong,China;3.Department of Infectious Diseases,the Affiliated Hospital of Qingdao University,Qingdao 266071,Shandong,China)
关键词:
慢性乙型肝炎; 聚乙二醇干扰素; 富马酸替诺福韦
Keywords:
Chronic hepatitis B; Pegylated interferon; Tenofovir fumarate
分类号:
R512.62
DOI:
10.3969/j.issn.1006-1959.2020.04.046
文献标志码:
A
摘要:
目的 探讨聚乙二醇干扰素α-2b（Peg-INF α-2b）联合富马酸替诺福韦治疗慢性乙型肝炎早期的临床疗效。方法 选择2018年6月~2019年6月我院就诊的慢性乙型肝炎患者62例，随机分为对照组（35例）和观察组（27例），对照组给予聚乙二醇干扰素治疗，观察组在此基础上联合替诺福韦治疗。比较两组治疗24周HBsAg定量、HBeAg定量、HBV-DNA 定量、ALT、AST、白细胞、中性粒细胞、血小板变化情况。结果 治疗24周两组均未出现HBsAg转阴，且两组HBsAg下降幅度比较，差异无统计学意义（P＞0.05）；实验组HBeAg下降幅度大于对照组，差异有统计学意义（P＜0.05）；但两组HBeAg转阴率比较，差异无统计学意义（P＞0.05）。治疗24周，对照组HBV-DNA转阴率低于观察组，差异有统计学意义（P＜0.05）。两组ALT、AST下降幅度，白细胞、中性粒细胞及血小板水平，流感样症状、骨髓抑制及脱发发生率比较，差异均无统计学意义（P＞0.05）。结论 聚乙二醇干扰素联合富马酸替诺福韦治疗慢性乙型肝炎24周HBV-DNA转阴率高，HBeAg下降幅度大，HBsAg、HBeAg转阴率及患者肝功能改善效果尚不明显，同时两药联用不增加不良反应。
Abstract:
Objective To investigate the early clinical efficacy of pegylated interferon α-2b (Peg-INF α-2b) combined with tenofovir fumarate in the treatment of chronic hepatitis B.Methods 62 patients with chronic hepatitis B who were treated in our hospital from June 2018 to June 2019 were randomly divided into a control group (35 cases) and an observation group (27 cases). The control group was treated with pegylated interferon The observation group was combined with tenofovir treatment on this basis. Changes in HBsAg quantification, HBeAg quantification, HBV-DNA quantification, ALT, AST, white blood cells, neutrophils, and platelets were compared between the two groups after 24 weeks of treatment.Results There was no HBsAg to negative in the two groups after 24 weeks of treatment, and there was no significant difference in the decrease in HBsAg between the two groups(P>0.05). The decrease in HBeAg was greater in the experimental group than in the control group,the difference was statistically significant(P<0.05).However, there was no significant difference in the HBeAg to negative rate between the two groups(P>0.05).After 24 weeks of treatment, the HBV-DNA negative rate in the control group was lower than that in the observation group,the difference was statistically significant(P<0.05).There was no significant difference in the decrease in ALT, AST, leukocyte, neutrophil, and platelet levels, the incidence of influenza-like symptoms, bone marrow suppression, and hair loss between the two groups(P>0.05).Conclusion Pegylated interferon combined with tenofovir fumarate in the treatment of chronic hepatitis B has a high HBV-DNA negative rate for 24 weeks, a large decrease in HBeAg, and no significant improvement in HBsAg, HBeAg negative rate and liver function. At the same time, the combination of two drugs did not increase adverse reactions.

参考文献/References:

[1]王贵强,王福生,成军,等.慢性乙型肝炎防治指南(2015年版)[J].中华实验和临床感染病杂志(电子版),2015,9(5):6-25. [2]李涛.ADAR1和ADAR2通过对MAVS基因的3’UTR进行RNA编辑影响HBV表达机制的研究[D].北京协和医学院,2017. [3]陈炎,陈亚蓓,陶荣芳.2018年美国《慢性乙型肝炎指导意见》介绍:慢性乙型肝炎特殊人群管理及治疗推荐更新[J].中国实用内科杂志,2018,38(S1):35-38. [4]Cooksley WG,Piratvisuth T,Lee SD,et al.Peginterferon alpha-2a(40 kDa):an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B[J].Journal of Viral Hepatitis,2003,10(4):298-305. [5]林志鹏,苏密龙,苏智军,等.替诺福韦联合聚乙二醇干扰素α2a注射液治疗耐药慢性乙型病毒性肝炎患者的临床研究[J].中国临床药理学杂志,2018(2):108-110. [6]娄鑫,郜玉峰,叶珺,等.聚乙二醇干扰素α-2a初治HBeAg阳性慢性乙型肝炎患者的效果及预测因素分析[J].临床肝胆病杂志,2018,34(05):995-1000. [7]Ferrari C.HBV and the immune response[J].Liver International,2015,35(Suppl1):121-128. [8]刘伟,杨智,仝巧云.乙型肝炎病毒e抗原抑制Fas介导的肝细胞凋亡[J].华中科技大学学报（医学版）,2019,48(2):21-26. [9]梁冰,殷海燕.聚乙二醇干扰素联合恩替卡韦治疗慢性乙肝的临床分析[J].中国继续医学教育,2018,10(29):135-137.

相似文献/References:

[1]林晓岚,郑丽花,陈苑莉,等.微信随访对慢性乙型肝炎患者抗病毒治疗效果和 生活质量的影响研究[J].医学信息,2018,31(10):164.[doi:10.3969/j.issn.1006-1959.2018.10.057]
　LIN Xiao-lan,ZHENG Li-hua,CHEN Yuan-li,et al.Effect of WeChat Follow-up on Antiviral Treatment and Quality of Life in Patients with Chronic Hepatitis B[J].Medical Information,2018,31(04):164.[doi:10.3969/j.issn.1006-1959.2018.10.057]
[2]林晓岚,陈苑莉.慢性乙型肝炎患者治疗依从性及其对生活质量的影响[J].医学信息,2018,31(13):168.[doi:10.3969/j.issn.1006-1959.2018.13.052]
　LIN Xiao-lan,CHEN Yuan-li.Treatment Compliance of Patients with Chronic Hepatitis B and its Influence on Quality of Life[J].Medical Information,2018,31(04):168.[doi:10.3969/j.issn.1006-1959.2018.13.052]
[3]吴 刚,吴锦瑜.HBeAg阴性慢性乙型肝炎患者血清25-羟基维生素D3的检测及临床意义[J].医学信息,2018,31(19):96.[doi:10.3969/j.issn.1006-1959.2018.19.028]
　WU Gang,WU Jin-yu.Detection and Clinical Significance of Serum 25-hydroxyvitamin D3 in Patients with HBeAg-negative Chronic Hepatitis B[J].Medical Information,2018,31(04):96.[doi:10.3969/j.issn.1006-1959.2018.19.028]
[4]叶向荣.恩替卡韦治疗慢性乙型肝炎病毒感染的临床价值评价[J].医学信息,2018,31(22):147.[doi:10.3969/j.issn.1006-1959.2018.22.043]
　YE Xiang-rong.Clinical Evaluation of Entecavir in Treatment of Patients with Chronic Hepatitis B Virus Infection[J].Medical Information,2018,31(04):147.[doi:10.3969/j.issn.1006-1959.2018.22.043]
[5]汪晓凤,邵和军.慢性乙型肝炎抗病毒治疗进展[J].医学信息,2019,32(04):39.[doi:10.3969/j.issn.1006-1959.2019.04.015]
　WANG Xiao-feng,SHAO He-jun.Progress in Antiviral Therapy for Chronic Hepatitis B[J].Medical Information,2019,32(04):39.[doi:10.3969/j.issn.1006-1959.2019.04.015]
[6]傅 蕊,李士欣,周国强,等.床旁超声预测慢性乙型肝炎患者胃镜检查围麻醉期误吸风险的临床价值[J].医学信息,2019,32(08):123.[doi:10.3969/j.issn.1006-1959.2019.08.035]
　FU Rui,LI Shi-xin,ZHOU Guo-qiang,et al.Clinical Value of Bedside Ultrasound in Predicting the Risk of Aspiration during Perioperative Anesthesia in Patients with Chronic Hepatitis B[J].Medical Information,2019,32(04):123.[doi:10.3969/j.issn.1006-1959.2019.08.035]
[7]张媛媛,徐 曼.慢性乙型肝炎患者e抗原消失的临床特点[J].医学信息,2019,32(10):105.[doi:10.3969/j.issn.1006-1959.2019.10.033]
　ZHANG Yuan-yuan,XU Man.Clinical Features of e Antigen Disappearance in Patients with Chronic Hepatitis B[J].Medical Information,2019,32(04):105.[doi:10.3969/j.issn.1006-1959.2019.10.033]
[8]罗 丹,梁惠卿,吴耀南.吴耀南教授基于“伏邪”理论治疗慢性乙肝的验案举隅[J].医学信息,2019,32(19):158.[doi:10.3969/j.issn.1006-1959.2019.19.052]
[9]周腾腾,郑 莹,梁恵卿,等.蛋白质组学在慢性乙型肝炎常见中医证型中的研究[J].医学信息,2019,32(20):30.[doi:10.3969/j.issn.1006-1959.2019.20.009]
　ZHOU Teng-teng,ZHENG Ying,LIANG Hui-qing,et al.Study on Proteomics in Common TCM Syndromes of Chronic Hepatitis B[J].Medical Information,2019,32(04):30.[doi:10.3969/j.issn.1006-1959.2019.20.009]
[10]陈 欢,李秀惠.急、慢性乙型肝炎及乙肝肝硬化患者 肝功能及血脂水平分析[J].医学信息,2019,32(12):67.[doi:10.3969/j.issn.1006-1959.2019.12.021]
　CHEN Huan,LI Xiu-hui.Analysis of Liver Function and Blood Lipid Levels in Patients with Acute, Chronic Hepatitis B and Hepatitis B Cirrhosis[J].Medical Information,2019,32(04):67.[doi:10.3969/j.issn.1006-1959.2019.12.021]
[11]张 瑜,路青华,曹海芳,等.聚乙二醇干扰素联合恩替卡韦对慢性乙型肝炎患者肝功能及肝纤维化的影响[J].医学信息,2021,34(17):114.[doi:10.3969/j.issn.1006-1959.2021.17.029]
　ZHANG Yu,LU Qing-hua,CAO Hai-fang,et al.Effect of Polyethylene Glycol Interferon,PEG-IFN Combined with Entecavir on Liver Function and Liver Fibrosis in Patients with Chronic Hepatitis B[J].Medical Information,2021,34(04):114.[doi:10.3969/j.issn.1006-1959.2021.17.029]

更新日期/Last Update: 2020-02-15